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httpcense.Abstract Objectives: Asthma imposes a growing burden on the society in terms of morbidity, qual-
ity of life, and healthcare costs. It has the highest morbidity amongst inﬂammatory lung diseases and
its prevalence continues to increase over the world. Inquiry into recent day or nighttime symptoms
alone underestimates the burden of asthma and may lead to inadequate treatment of asthma. The
aim of the present work is to evaluate the role of nitric oxide (NO) and hydrogen ion concentration
(pH) levels in exhaled breath condensate (EBC) in cases of controlled bronchial asthma.
Patients andmethods: The present studywas conducted on 49 controlled asthmatic patients and 12
control subjects. All patientswere subjected to thorough history taking, complete clinical examination
and plain postero-anterior chest X-ray. All asthmatics and control subjects were subjected to routine
laboratory investigations, spirometric study, EBC collection, processing and analysis for its content of
both nitric oxide end products: nitrite and nitrate (NOx) and pH.
Results: All asthmatics representedGroup ITwhichwas further divided intoGroup Ia: 34 patients
on regular inhaled corticosteroid (ICS) therapy andGroup Ib: 15 patients on no regular therapy. The
control subjects represented Group II. The forced vital capacity (FVC), forced expiratory volume in
the ﬁrst second (FEV1), FEV1/FVC, peak expiratory ﬂow rate (PEFR) and forced expiratory ﬂow
during themiddle portion of a forced expiration (FEF 25–75%)were signiﬁcantly lower in asthmatics
than control subjects. The EBC-NOx mean ± SD in lmol/L in Group IT (5.99 ± 1.63), in Group Ia
(5.27 ± 1.26) and in Group Ib (7.63 ± 1.15) were signiﬁcantly higher than in Group II (3.66 ± 0.67)
with, respectively (p= 0.000), (p= 0.000) and (p= 0.000); and was signiﬁcantly higher in Group Ib
than Group Ia (p= 0.000). The EBC-pH mean ± SD in Group IT (7.32 ± 0.27), in Group Ia7973726.
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248 A. Elhefny et al.(7.35 ± 0.25) and in Group Ib (7.27 ± 0.3) were signiﬁcantly lower than in Group II (7.82 ± 0.09)
with, respectively (p= 0.000), (p= 0.000) and (p= 0.000); with no signiﬁcant difference between
Group Ia and Group Ib. The EBC-NOx was signiﬁcantly directly correlated to eosinophils count
(p= 0.017) and neutrophils count (p= 0.002); and inversely correlated to FEV1 (p= 0.016),
FEV1/FVC (p= 0.001), PEFR (p= 0.030) and EBC-pH (p= 0.003). The EBC-pHwas signiﬁcantly
inversely correlated to eosinophils count (p= 0.017) and neutrophils count (p= 0.036); and directly
correlated to FVC (p= 0.004), FEV1 (p= 0.004) and PEFR (p= 0.000).
Conclusion: EBC-NOx is signiﬁcantly higher and EBC-pH is signiﬁcantly lower in asthmatic
patients than in control subjects. Asthmatics receiving ICS have a lower EBC-NOx level than those
not. EBC-NOx and EBC-pH were signiﬁcantly correlated and both of them showed signiﬁcant cor-
relations with spirometric parameters of airway obstruction.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Bronchial asthma is a chronic inﬂammatory disorder of the air-
ways in which many cells and cellular elements play a role. The
chronic inﬂammation is associated with airway hyper-respon-
siveness that leads to recurrent episodes of wheezing, breathless-
ness, chest tightness, and coughing, particularly at night or in
the early morning. These episodes are usually associated with
widespread, but variable, airﬂow obstruction within the lung
that is often reversible either spontaneously or with treatment
[1]. Asthma imposes a growing burden on the society in terms
of morbidity, quality of life, and healthcare costs. Global asth-
ma comprises three components: short-term symptom burden,
long-term symptom burden, and functional impact. Inquiry into
recent day or nighttime symptoms alone underestimates the bur-
den of asthma and may lead to inadequate treatment of asthma
based on national guideline recommendations [2]. In 2004, it
was reported that about 300 million people worldwide have
asthma and by 2025 it has been estimated that a further 100 mil-
lion will be affected. Asthma accounts for one in every 250
deaths worldwide and 1% of all disability adjusted life years.
In overall health terms, chronic symptoms of asthma account
for 8% of self reported poor health in 18–64 year old and
3.5% of days of limited activity, putting asthma above diabetes
but below arthritis as a chronic health problem [3].
Asthma control may be deﬁned in a variety of ways. It may
indicate disease prevention, or even cure; but in asthma, where
neither of these are realistic options at present, it refers to con-
trol of the manifestations of disease. Control of asthma has
been deﬁned by guidelines. Because assessment of asthma con-
trol is independent of asthma medications, asthma control is
dissociated from asthma severity classiﬁcation [4].
Exhaled breath condensate (EBC) contains several compo-
nents. The principal component is condensed water vapor. This
ﬂuid represents nearly all of the volume (>99%) of ﬂuid col-
lected in EBC. Only a small fraction of the condensate is derived
from respiratory droplets containing nonvolatile molecules,
which can be both hydrophobic and hydrophilic [5]. Water-sol-
uble volatile compounds are absorbed by the condensing water
during collection. During EBC collection exhaled breath is di-
rected through a cooling device, resulting in a liquid or solid
phase accumulation of exhaled breath constituents depending
on the condenser temperature. During tidal breathing, the liber-
ated aerosol particles range between 0.1–4 particles cm3 with a
mean diameter of 0.3 lm [6]. The constituents of EBC are inﬂu-enced by smoking, alcohol consumption, exercise, type and rate
of breathing, nasal and salivary contamination, environmental
temperature and humidity. Also, the immunoassays used can
lead to undesirable variability [7].
Nitric oxide (NO) is synthesized in mammalian cells by the
oxidation of L-arginine to NO and L-citrulline. This reaction is
catalysed by enzymes called NO synthases (NOS). Nitric oxide
synthases are initially broadly classiﬁed into either constitutive
(cNOS) or inducible (iNOS) [8]. The nitric oxide end products
(NOx) are nitrite and nitrate.
NO is recognized as a key signaling molecule in a wide vari-
ety of biological functions, and NO research affects all
branches of medicine. In the lung, NO is formed on demand
in many generator cells and acts on nearby target cells such
as vascular or bronchial smooth muscle cells [9]. Once pro-
duced, NO is freely diffusible and may enter many cells [8].
Smoking increases NO levels in EBC. NO in the lungs, acts
as a vasodilator, bronchodilator and non-adrenergic non-cho-
linergic neurotransmitter, an important mediator of the
inﬂammatory response and plays a major role in the pulmon-
ary host defence mechanism [9]. However, studies in humans
have shown that inhalation of NO has only a small effect on
resistance and airway calibre, both in normal and asthmatic
subjects, so it is unlikely that this will prove a major function
of NO in vivo. It seems likely that the high exhaled nitric oxide
(eNO) levels in asthma reﬂect a pathological state produced by
the chronic inﬂammation that is characteristic of asthma. Pro-
inﬂammatory cytokines are secreted in asthma and result in
inﬂammatory cell recruitment and iNOS induction [10].
The measurement of EBC-pH has been proposed as a
promising noninvasive tool in the assessment of patients with
asthma. EBC-pH correlates well with other indices of airway
inﬂammation; notably eosinophilic or neutrophilic ones [11].
It was found to decrease during acute exacerbations in adults,
and to normalize with anti-inﬂammatory therapy. The possi-
bility exists that this simple assay may be a useful surrogate
for invasive or more complicated attempts at assessment of air-
way inﬂammation [12].
The aim of the present work is to evaluate the role of NO
and pH levels in EBC in cases of controlled asthma.
Patients and methods
This study was conducted in the chest disease department in
main Alexandria University Hospital. It was carried out on
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Exclusion criteria from the study comprised smokers, subjects
with renal or hepatic diseases and asthma patients admitted to
the hospital in the last 6 months.
Detailed informed consent was taken from all patients and
control subjects. All asthmatic patients were subjected to thor-
ough history taking, complete clinical examination and plain
postero-anterior chest X-ray.
All subjects, asthmatic patients and control, were subjected
to routine laboratory investigations including complete blood
picture, renal and liver function tests and fasting glucose level.
They were then subjected to spiromtric study (Chestgraph HI-
701). The American Thoracic Society/European Respiratory
Society standards [13] were followed for spirometric measure-
ments. From the ﬂow-volume loop, the forced vital capacity
(FVC), forced expiratory volume in the ﬁrst second (FEV1),
ratio of FEV1 to FVC (FEV1/FVC), peak expiratory ﬂow rate
(PEFR) and forced expiratory ﬂow during the middle portion
of a forced expiration (FEF 25–75%) were recorded. Finally,
exhaled breath condensate (EBC) was collected from all sub-
jects. Breathing air through a cooling system results in conden-
sation. The condensing chamber used consisted of an
immersed Teﬂon (polytetraﬂuoroethylene) lined tube in an
ice-ﬁlled container with a double-wall condenser system
(Fig. 1) [14]. The subjects were instructed to sit comfortably,
breathe tidally directly into a mouthpiece connected to the
tube. No nose clips were used to prevent opening of the naso-
pharyngeal velum, thereby contaminating the exhaled breath
with nasal air. If the subjects salivated, they were instructed
to swallow. They would breathe so for at least 10 min and
an amount of 1–3 ml of EBC was obtained. The EBC was then
collected as icy water at 20 C and immediately stored at
70 C [11].
The nitric oxide end products: nitrite and nitrate (NOx)
concentrations were determined by simple Griess reaction
[15]. The ﬁrst step was nitrate reduction and deproteinization.
An aliquot of 100 ll of breath condensate was incubated with
50 ll nitrate reductase and 50 ll of reduced nicotinamide ade-
nine dinucleotide phosphate (NADPH) for 30 min at room
temperature. After the reduction, 100 ll of the mixture was
deproteinized by incubation overnight with 900 ll of a mixture
of methanol and diethyl ether in a ratio of 3 to 1. After theFigure 1 Schematic representation of the collection apparatus in
the present study.overnight incubation, the sample was centrifuged at
10000 rpm for 10 min at 4 C and the supernatant was used
for determination of nitrite. Aliquots of 600 ll of this superna-
tant, 150 ll of 6.5 M HCl (moles per liter hydrochloric acid),
and 150 ll of 37.5 mM sulphanilic acid were added to a centri-
fuge tube and then incubated at 4 C for 30 min. After incuba-
tion, 150 ll of 12.5 mM N-(1-naphthyl)ethylenediamine was
added and the sample was centrifuged at 10000 rpm for
10 min at 4 C. The absorbance of the clear supernatant was
measured at 540 nm. The NOx concentration was measured
using standard curve for sodium nitrite constructed by prepar-
ing serial concentration of sodium nitrite (0–50 lmol/L).
Hydrogen ion concentration (pH)wasmeasured by a pHmeter
with a silicon chip sensor (Shindengen pHBoy-P2, Tokyo, Japan).
Calibration was performed using buffers of pH 4.0, 7.0, and 10.0
before measuring the EBC samples. The sample was poured into
a clean small beaker and the electrodewas inserted so as to be com-
pletely covered by the sample.When a stable reading was reached,
it was taken. Immediately after themeasurement the electrode was
rinsed with potassium chloride solution (0.5 M) and kept im-
mersed there till the next measurement.
Data were processed and analyzed by the software statisti-
cal package of social science (SPSS) version 13. Data were ex-
pressed as mean ± standard deviation (SD). Comparison of
means between every two groups was done using paired t-test.
Correlation was tested using Pearson correlation coefﬁcient.Results
We classiﬁed the subjects of the present study into Group IT:
49 controlled asthmatic patients and Group II: 12 control sub-
jects. Group IT was further divided into two groups: Group Ia:
34 patients on regular inhaled corticosteroid therapy and
Group Ib: 15 patients on no regular therapy, receiving bron-
chodilators only (ß2 agonist) when needed.
Age, body mass index, total and differential white blood cell
count in all groups are shown in Table 1. Group Ia included 6
males and 28 females; their age ranged between 20 and 60 years
with a mean ± SD of 40.77 ± 10.97 years and their body mass
index (BMI) calculated by Quetelet’s formula: Weight/Height2,
ranged between 19.6 and 37.2 kg/m2 with a mean ± SD of
27.86 ± 4.88 kg/m2. Group Ib included 2 males and 13 females;
their age ranged between 21 and 56 years with a mean ± SD of
39.33 ± 10.29 years and their BMI ranged between 19.7 and
39.52 kg/m2 with a mean ± SD of 28.41 ± 5.95 kg/m2. Group
II included 2 males and 10 females; their age ranged between
29 and 38 years with a mean ± SD of 33.17 ± 3.16 years and
their BMI ranged between 19.3 and 26.95 kg/m2 with a
mean ± SD of 24.06 ± 2.54 kg/m2.
The total white blood cell (WBC) count in Group Ia ranged
between 4100 and 9800 cells/cubic milliliter (cell/cml) with a
mean ± SD of 6558.8 ± 1615.3 cell/cml, in Group Ib between
5600 and 9600 cell/cml with a mean ± SD of 8126.67 ±
1289.22 cell/cml and in Group II between 4000 and 8300 cell/
cml with a mean ± SD of 5825 ± 1312.27 cell/cml. There was
a statistical signiﬁcant difference between Group IT and Group
II (p= 0.013); between Group Ib and Group II (p= 0.000);
and between Group Ia and Group Ib (p= 0.001). The eosino-
philic percentage in Group Ia ranged between 3% and 6% with
a mean ± SD of 4.15 ± 0.86%, in Group Ib between 3 and 6%
with a mean ± SD of 4.07 ± 0.96% and in Group II between
Table 1 Age, body mass index, total and differential white blood cell count in all groupsa.
Age (years) BMI (kg/m2) WBC (cell/cml) E (%) N (%) L (%) M (%)
Group I T 7038.7 ± 1676.7 4.1 ± 0.8 58.4 ± 3.7 33.4 ± 3.7 4.0 ± 1.2
a 40.7 ± 10.9 27.8 ± 4.8 6558.8 ± 1615.3 4.1 ± 0.8 57.9 ± 3.3 33.5 ± 3.4 4.2 ± 1.1
b 39.3 ± 10.2 28.4 ± 5.9 8126.6 ± 1289.2 4.0 ± 0.9 59.4 ± 4.6 33 ± 4.6 3.5 ± 1.1
Group II 33.1 ± 3.1 24.0 ± 2.5 5825 ± 1312.2 3.5 ± 0.5 61.5 ± 2.1 29.2 ± 1.9 5.5 ± 0.7
t-valueb 2.70** 2.76** 3.85** 5.38** 5.29**
p 0.013 0.010 0.001 0.000 0.000
t-valuec 1.56 2.69** 4.27** 5.39** 4.19**
p 0.131 0.011 0.000 0.000 0.000
t-valued 4.56** 1.67 1.62 2.85** 5.54**
p 0.000 0.109 0.119 0.010 0.000
t-valuee 3.620** 0.279 1.082 0.443 2.140*
p 0.001 0.783 0.292 0.662 0.041
BMI: Body mass index, kg/m2: kilogram/square meter; WBC: white blood cell count; cell/cml: cells/cubic milliliter; E: eosinophils, %: percent;
N: neutrophils; L: lymphocytes; M: monocytes.
a Data are presented as mean ± SD.
b Between Group IT and Group II.
c Between Group Ia and Group II.
d Between Group Ib and Group II.
e Between Group Ia and Group Ib.
* Signiﬁcant at level 0.05.
** Signiﬁcant at level 0.01.
250 A. Elhefny et al.3% and 4% with a mean ± SD of 3.58 ± 0.52%. There was a
statistical signiﬁcant difference between Group IT and Group
II (p= 0.010); and between Group Ia and Group II
(p= 0.011). The neutrophilic percentage in Group Ia ranged
between 51% and 64% with a mean ± SD of 57.97 ± 3.34%,
in Group Ib between 52% and 64% with a mean ± SD of
59.4 ± 4.61% and in Group II between 57% and 65% with a
mean ± SD of 61.58 ± 2.15%. There was a statistical signiﬁ-
cant difference between Group IT and Group II (p= 0.001);
and between Group Ia and Group II (p= 0.000). The lympho-
cytic percentage inGroup Ia ranged between 28%and 40%with
amean ± SDof 33.59 ± 3.41%, inGroup Ib between 28%and
41% with a mean ± SD of 33 ± 4.614% and in Group II be-
tween 27% and 33% with a mean ± SD of 29.25 ± 1.91%.
There was a statistical signiﬁcant difference between Group IT
and Group II (p= 0.000); between Group Ia and Group II
(p= 0.000); and between Group Ib and Group II (p= 0.010).
The monocytic percentage in Group Ia ranged between 2%
and 6% with a mean ± SD of 4.29 ± 1.19% in Group Ib be-
tween 2% and 6% with a mean ± SD of 3.533 ± 1.125% and
in Group II between 4% and 7% with a mean ± SD of
5.58 ± 0.79%. There was a statistical signiﬁcant difference be-
tween Group IT and Group II (p= 0.000); between Group Ia
and Group II (p= 0.000); between Group Ib and Group II
(p= 0.000); and between Group Ia and Group Ib (p= 0.041).
Spirometric data, EBC-NOx and EBC-pH in all groups are
shown in Table 2. The percent of predicted FVC in Group Ia
ranged between 62.9% and 98% with a mean ± SD of
82.45 ± 8.06%, in Group Ib between 63.5% and 85% with a
mean ± SD of 78.47 ± 5.29% and in Group II between
78% and 98% with a mean ± SD of 88.4 ± 6.76%. There
was a statistical signiﬁcant difference between Group IT and
Group II (p= 0.005); between Group Ia and Group II
(p= 0.021); between Group Ib and Group II (p= 0.000);
and between Group Ia and Group Ib (p= 0.047). The percent
of predicted FEV1 in Group Ia ranged between 60.7% and
90% with a mean ± SD of 77.66 ± 7.92%, in Group Ib be-
tween 70% and 87.79% with a mean ± SD of79.79 ± 4.73% and in Group II between 87.98% and
102.8% with a mean ± SD of 92.68 ± 4.03%. There was a
statistical signiﬁcant difference between Group IT and Group
II (p= 0.000); between Group Ia and Group II (p= 0.000);
and between Group Ib and Group II (p= 0.000). The
FEV1/FVC in Group Ia ranged between 60 and 83.26 with a
mean ± SD of 73.12 ± 6.44, in Group Ib between 65.38 and
88.73 with a mean ± SD of 72.9 ± 5.76 and in Group II be-
tween 80.47 and 91.5 with a mean ± SD of 85.2 ± 4.12. There
was a statistical signiﬁcant difference between Group IT and
Group II (p= 0.000); between Group Ia and Group II
(p= 0.000); and between Group Ib and Group II
(p= 0.000). The percent of predicted FEF 25–75% in Group
Ia ranged between 65.5% and 97% with a mean ± SD of
76.91 ± 9.21%, in Group Ib between 64% and 94% with a
mean ± SD of 77.7 ± 9.13% and in Group II between 84%
and 98% with a mean ± SD of 89.67 ± 3.96%. There was a
statistical signiﬁcant difference between Group IT and Group
II (p= 0.000); between Group Ia and Group II (p= 0.000);
and between Group Ib and Group II (p= 0.000). The percent
of predicted PEFR in Group Ia ranged between 61.4% and
90% with a mean ± SD of 71.87 ± 6.93%, in Group Ib be-
tween 62% and 85% with a mean ± SD of 70.73 ± 6.32%
and in Group II between 75.6% and 90.7% with a mean ± SD
of 84.54 ± 4.62%. There was a statistical signiﬁcant difference
between Group IT and Group II (p= 0.000); between Group
Ia and Group II (p= 0.000); and between Group Ib and
Group II (p= 0.000). There was a statistical signiﬁcant differ-
ence between Group IT and Group II (p= 0.000); between
Group Ia and Group II (p= 0.000); and between Group Ib
and Group II (p= 0.000).
The EBC-NOx in Group Ia ranged between 3.44 and
7.65 lmol/L with a mean ± SD of 5.27 ± 1.26 lmol/L, in
Group Ib between 5.33 and 9.3 lmol/L with a mean ± SD
of 7.63 ± 1.15 lmol/L and in Group II between 2.7 and
4.75 lmol/L with a mean ± SD of 3.66 ± 0.67 lmol/L. There
was a statistical signiﬁcant difference between Group IT and
Group II (p= 0.000); between Group Ia and Group II
Table 2 Spirometric data, EBC-nitric oxide end products and EBC-pH in all groupsa.
FVC
(%pred)
FEV1
(%pred)
FEV1/FVC FEF25–75%
(%pred)
PEFR
(%pred)
EBC-NOx
(lmol/L)
EBC-pH
Group I T 81.23 ± 7.5 78.31 ± 7.12 73.05 ± 6.18 77.15 ± 9.1 71.52 ± 6.7 5.99 ± 1.63 7.32 ± 0.27
a 82.45 ± 8.06 77.66 ± 7.92 73.12 ± 6.44 76.91 ± 9.21 71.87 ± 6.93 5.27 ± 1.26 7.35 ± 0.25
b 78.47 ± 5.29 79.79 ± 4.73 72.9 ± 5.76 77.7 ± 9.13 70.73 ± 6.32 7.63 ± 1.15 7.27 ± 0.3
Group II 88.4 ± 6.76 92.68 ± 4.03 85.2 ± 4.12 89.67 ± 3.96 84.54 ± 4.62 3.66 ± 0.673 7.82 ± 0.09
t-valueb 3.21** 9.29** 8.20** 7.23** 7.93** 7.67** 10.45**
p 0.005 0.000 0.000 0.000 0.000 0.000 0.000
t-valuec 2.48* 8.39** 7.44** 6.54** 7.09** 5.55** 9.10**
p 0.021 0.000 0.000 0.000 0.000 0.000 0.000
t-valued 4.17** 7.63** 6.46** 4.57** 6.55** 11.14** 6.62**
p 0.000 0.000 0.000 0.000 0.000 0.000 0.000
t-valuee 2.053* 1.168 0.117 0.279 0.564 6.40** 0.929
p 0.047 0.249 0.908 0.782 0.577 0.000 0.363
EBC: exhaled breath condensate; FVC: forced vital capacity; %pred: percent of predicted; FEV1: Forced expiratory volume in the ﬁrst second;
FEF25–75%: forced expiratory ﬂow rate middle portion; PEFR: peak expiratory ﬂow rate; NOx: nitric oxide end products; lmol/L: micromoles
per liter; pH: hydrogen ion concentration.
a Data are presented as mean ± SD.
b Between Group IT and Group II.
c Between Group Ia and Group II.
d Between Group Ib and Group II.
e Between Group Ia and Group Ib.
* Signiﬁcant at level 0.05.
** Signiﬁcant at level 0.01.
Table 3 Correlations of EBC-NOx and EBC-pH with total and differential white blood cell count.
WBC E (c) E (%) N (c) N (%) L (c) L (%) M (c) M (%)
EBC-NOx r 0.420* 0.305* 0.080 0.392* 0.059 0.445* 0.186 0.059 0.437*
p 0.001 0.017 0.541 0.002 0.651 0.000 0.151 0.649 0.000
EBC-pH r 0.325* 0.305 * 0.208 0.269 * 0.223 0.380 * 0.251 * 0.026 0.244
p 0.010 0.017 0.107 0.036 0.084 0.002 0.051 0.842 0.058
EBC: exhaled breath condensate; NOx: nitric oxide end products; pH: hydrogen ion concentration; r: correlation coefﬁcient; p: level of
signiﬁcance; WBC: white blood cell count; E: eosinophils; c: count;%: percent; N: neutrophils; L: lymphocytes; M: monocytes.
* Statistical signiﬁcance at p< 0.05.
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Figure 2 The signiﬁcant direct correlation between exhaled
breath condensate nitric oxide end products (NOx) and eosino-
philic count (EC).
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between Group Ia and Group Ib (p= 0.000). The EBC-pH in
Group Ia ranged between 6.7 and 7.8 with a mean ± SD of
7.35 ± 0.25, in Group Ib between 6.8 and 7.7 with a
mean ± SD of 7.27 ± 0.3 and in Group II between 7.6 and
7.9 with a mean ± SD of 7.82 ± 0.09. There was a statistical
signiﬁcant difference between Group IT and Group II
(p= 0.000); between Group Ia and Group II (p= 0.000);
and between Group Ib and Group II (p= 0.000).
The correlations of both EBC-NOx and EBC-pH with total
and differential white blood cell count are shown in Table 3.
The EBC-NOx was signiﬁcantly directly correlated to total
white blood cell count (p= 0.001), eosinophils count
(p= 0.017) (Fig. 2), neutrophils count (p= 0.002) and lym-
phocytes count (p= 0.000). The EBC-NOx was also signiﬁ-
cantly inversely correlated to monocytes percent (p= 0.000).
The EBC-pH was signiﬁcantly inversely correlated to total
white blood cell count (p= 0.010), eosinophils count
(p= 0.017) (Fig. 4), neutrophils count (p= 0.036), lympho-
cytes count (p= 0.002) and lymphocytes percent (p= 0.051).
The correlations of EBC-NOx and EBC-pH with spiromet-
ric parameters are shown in Table 4. The EBC-NOx wassigniﬁcantly inversely correlated to FEV1 (p= 0.016)
(Fig. 3), FEV1/FVC (p= 0.001), PEFR (p= 0.030) and
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Figure 4 The signiﬁcant inverse correlation between exhaled
breath condensate hydrogen ion concentration (pH) and eosino-
philic count (EC).
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Figure 3 The signiﬁcant inverse correlation between exhaled
breath condensate nitric oxide end products (NOx) and percent of
predicted forced expiratory volume in the ﬁrst second (FEV1%).
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Figure 6 The signiﬁcant inverse correlation between exhaled
breath condensate nitric oxide end products (NOx) and exhaled
breath condensate hydrogen ion concentration (pH).
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Figure 5 The signiﬁcant direct correlation between exhaled
breath condensate hydrogen ion concentration (pH) and percent
of predicted forced expiratory volume in the ﬁrst second
(FEV1%).
252 A. Elhefny et al.EBC-pH (p= 0.003) (Fig. 6). The EBC-pH was signiﬁcantly
directly correlated to FVC (p= 0.004), FEV1 (p= 0.004)
(Fig. 5) and PEFR (p= 0.000).
Discussion
Inﬂammatory diseases of the lungs and airways have signiﬁ-
cant medical and economic burden. Asthma has the highestTable 4 Correlations of EBC-NOx and EBC-pH with spirometric
FVC FEV1
EBC-NOx r 0.175 0.306 *
p 0.177 0.016
EBC-pH r 0.363 * 0.368 *
p 0.004 0.004
EBC: exhaled breath condensate; NOx: nitric oxide end products; pH
signiﬁcance; FVC: forced vital capacity; FEV1: forced expiratory volum
portion; PEFR: peak expiratory ﬂow rate.
* Statistical signiﬁcance at p< 0.05.morbidity amongst inﬂammatory lung diseases and its preva-
lence continues to increase over the world. The current asthma
management guideline relies on the monitoring of respiratory
function and symptoms, however the quantiﬁcation of airway
inﬂammation may provide additional information for both the
diagnosis and management of asthma. Previous studies have
demonstrated that the addition of alternative monitoringparameters and with each other.
FEV1/FVC FEF 25–75% PEFR EBC-pH
0.426 * 0.157 0.277 * 0. 371*
0.001 0.227 0.030 0.003
0.217 0.239 0.504 * –
0.092 0.064 0.000 –
: hydrogen ion concentration; r: correlation coefﬁcient; p: level of
e in the ﬁrst second; FEF25-75%: forced expiratory ﬂow rate middle
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tric oxide concentration, to the current guidelines on drug dose
adjustment leads to improved outcomes [16].
Exhaled breath condensate (EBC) has been demonstrated
as a noninvasive method to evaluate airway inﬂammation,
chronic cough and cough variant asthma through various
inﬂammatory mediators and markers, which helps in the
understanding of the pathophysiology of asthma; as it reﬂects
changes in the airway lining ﬂuid [17]. Levels of some EBC
molecules from samples obtained directly from the lower air-
ways through a tracheotomy tube and those collected through
the mouth have been compared. Concentrations of adenosine,
thromboxane B2, pH, hydrogen peroxide and 8-isoprostane
were not signiﬁcantly different between these samples; suggest-
ing that most of these molecules are added to EBC samples in
the lower airways. In contrast the concentration of ammonia is
substantially lower in EBC samples obtained through trache-
otomy tube than in those collected through the mouth suggest-
ing that most of this compound is added to the sample from
the upper airways or oropharynx [5,6].
EBC collection is easy and can be used in children and in
outpatient clinics without much training [7]. We found it a rel-
atively easy procedure. EBC volume was linearly related to the
volume expired [18]. Generally, with 10 min of tidal breathing
1–3 mL of EBC can be collected from resting adult subjects
[11]. For standardization of EBC sampling some investigators
have suggested collection for a time over which a pre-deﬁned
volume of air of a hundred liters in adults is expired, instead
of setting ﬁxed collection time. No published data are avail-
able, however, on studies comparing these two approaches
with respect to reproducibility of molecule concentrations [18].
The role of NO as a mediator was described in 1987 [19]. In
1991, it was observed that NO was identiﬁed in the exhaled
breath of animals and humans [20]. Exhaled nitric oxide is
the most widely studied and standardized non-invasive bio-
marker that evaluates airway inﬂammation in asthma. Exhaled
NO levels were reported to be higher in asthmatics than in
healthy subjects [21–23]. Moreover, asthma was found to be
predictive of increased values of eNO [21]. Exhaled nitric oxide
end products (eNOx) were reported to be stable metabolites of
NO and reliable indicators of NO synthesis in humans [24,25].
The present study demonstrated a signiﬁcantly higher level of
eNOx in the asthmatic group than the control group. The
eNOx have been reported to be higher in asthmatics than in
healthy subjects before [26]. The eNOx levels in asthmatic chil-
dren was also found to be signiﬁcantly higher than those mea-
sured in patients with cough or after a wheezy episode due to
viral infection [26]. It has been proposed as a tool to assess
exacerbation in asthmatics [24].
During inﬂammatory processes in asthmatics, free radical
production occurs in the airway and is strong enough to
overcome antioxidant defenses and subsequent lipid peroxi-
dation in bronchial lining ﬂuid of lower airways leading to re-
lease of mediators as NO. Although the cellular source of
exhaled NO has not yet been unequivocally identiﬁed, studies
suggest that the NO in exhaled air is primarily produced by
cells in the airway surface, such as epithelial cells rather than
the cells of the pulmonary circulation. NO in the airways has
been recognized as a pro-inﬂammatory mediator in asthma,
and in fact it has been suggested that elevated levels of NO
in exhaled breath may reﬂect ongoing airways inﬂammation
[27].Elevated eNO was found to have a high degree of discrim-
inating power and greater diagnostic accuracy than conven-
tional tests such as asthma questionnaire, pulmonary
function test, methacholine challenge and speciﬁc immuno-
globulin E for the screening of patients with a suspected diag-
nosis of asthma [21]. Hence, eNO was found to be a reliable
and sensitive screening tool to diagnose asthma in high-risk
untreated patients [21]; a screening tool to predict [9,21,28]
and monitor asthma exacerbation [27]; to assess compliance
and response to therapy [27]; and to study asthma control
[9,27]. In fact, it was even reported to provide a longer term in-
dex of asthma control than simple spirometry [27].
The recommended long-term control medications that are
taken daily on a long-term basis to achieve and maintain con-
trol of persistent asthma include many drugs. Inhaled cortico-
steroids (ICS) are the most potent and consistently effective
long-term control medication for asthma. Their clinical effects
include reduction in severity of symptoms; improvement in
asthma control and quality of life; reduction in the decline of
airway function; improvement in spirometry; diminished air-
way hyper-responsiveness; lessening exacerbations; reduction
in systemic corticosteroid courses, emergency care, hospitaliza-
tions, and deaths due to asthma; and possibly the attenuation
of loss of lung function. Therefore, ICS could possibly inﬂu-
ence remodeling through their anti-inﬂammatory effects. How-
ever, ICS are much less effective in reversing airway
remodeling than inﬂammation [1,29,30].
We found that the level of eNOx was signiﬁcantly lower in
asthmatic patients receiving ICS compared to those on bron-
chodilator therapy alone. The mean value of eNO level was re-
ported before to be higher in asthmatics not using ICS or on
bronchodilator therapy only [28] Previous studies have demon-
strated that eNO in asthmatics decreased signiﬁcantly after
glucocorticoid therapy administered either by oral or inhaled
route, in comparison to their level measured before treatment
and approaches those levels seen in normal subjects [9,22]. It
was postulated in a previous study that eNO was useful in
the clinical management of asthmatic patients treated with
ICS. The eNO levels were correlated with asthma symptoms,
disease score, and reversibility of airﬂow obstruction [31].
The eNO was found also to persist above the normal level in
a group with difﬁcult asthma in whom symptoms persist de-
spite the use of oral steroid treatment [32].
The eNO has been successfully used to monitor the re-
sponse of anti-inﬂammatory treatment with ICS in asthma.
It was reported as a sensitive and rapid marker of the dose-
dependent effect of steroid treatment, or asthma deterioration;
hence useful in optimizing treatment [21,33].
Healthy subjects produce low levels of eNO, which presum-
ably originates from cNOS activity [34]. Nitric oxide is also
formed de novo by an inducible isoform of NOS through gene
activation. Expression of this inducible form of NOS is stimu-
lated by endogenous cytokines resulting in the synthesis of NO
[35]. Elevated levels of NO are strongly associated with condi-
tions known to increase inﬂammation in asthma, such as aller-
gen provocation challenge, pollen season, animal allergy, or
indoor allergens in sensitized asthma patients [36]. Inhaled cor-
ticosteroid decreases eNO both after an acute asthma exacer-
bation and in stable asthmatics, presumably via suppression
of eosinophilic inﬂammation and iNOS, but not in normal
subjects [34]. NO produced in small quantities locally by cNOS
activation may have a beneﬁcial role in neural transmission
254 A. Elhefny et al.and in bacterial defence; but have deleterious effects when pro-
duced in much higher concentrations by iNOS as it could con-
tribute to the hyperaemia of asthmatic airways through its
vasodilatory effect, and this in turn could increase plasma exu-
dation and inﬂammation. NO is chemotactic for a variety of
inﬂammatory cells and also plays a key role in the modulation
of eotaxin, a chemokine that has selective chemotactic activity
for eosinophils [10,36]. It may also have cytotoxic effects that
could contribute to the epithelial shedding and through its
reaction with superoxide, produces peroxynitrite, which is a
powerful oxidant that can react with several proteins and lip-
ids. Beneﬁcially, corticosteroids inhibit NO formation when
iNOS has been induced from a variety of different stimuli,
but basal cNOS expression is unaffected [35–37]. However, it
was reported that a fall in eNO does not necessarily mean that
the inﬂammation is well treated, but may merely signify that a
certain dose of the drug has reached the airways. Regardless,
this by itself is useful information about the compliance with
treatment [38].
In the present study, the EBC-pH was signiﬁcantly lower in
both asthmatic groups than in the control one. The pH of the
expired breath condensate might be a simple, noninvasive,
inexpensive, and easily repeatable procedure for the evaluation
of the inﬂammatory process in airway diseases [39,40]. Patients
with moderate asthma had signiﬁcantly lower values compared
with mild asthma and control subjects; however, pH values
were signiﬁcantly lower in patients with COPD and bronchiec-
tasis compared with asthmatic patients [39]. Although EBC-
pH is one of the most important markers measured in the
EBC, the uncertainty of its assays is derived from the instabil-
ity of the EBC-pH [40]. This latter exhibits good repeatability
in long-term assessment but it tends to ﬂuctuate more in asth-
matics than in healthy subjects. Its variability in asthma was
not inﬂuenced by changes in clinical status; rather, cigarette
smoking may be implicated in this [41].
It was observed before that EBC-pH in asthmatic subjects
rose back to normal after successful treatment with steroids
[12,42]. Endogenous airway acidiﬁcation depends on the
amount of acid provided to the airways by inﬂammatory cells
and also to the presence of buffers, such as ammonia. Ammo-
nia is produced in airway epithelial cells by glutamine in the
presence of glutaminase, and this production is inhibited by
cytokines (interferon-c and tumor necrosis factor-a), whereas
corticosteroid administration has the opposite effect [40]. Nev-
ertheless, we found no signiﬁcant difference in EBC-pH be-
tween asthmatic patients receiving ICS and those on
bronchodilator therapy alone.
The present study showed a signiﬁcant inverse correlation
between EBC-pH and EBC-NOx. Such inverse correlation
was previously reported [39]. It was demonstrated that the
levels of eNO and nitrite were dependent on airway acidosis,
showing low airway pH levels in untreated asthmatics that re-
turned to normal following inhaled corticosteroid treatment.
It was suggested that pH was a determinant of NOx concen-
trations and bioactivities in the airways of subjects with acute
asthma. The pH conditions in the airways favored proton-
ation of airway nitric oxide to form nitrous acid resulted in
liberation of NO gas. Endogenous airway ﬂuid acidiﬁcation
depleted nitric oxide in the airways. This raised the possibility
that nitric oxide may serve as a NOx reservoir, converted to
NO by airway acidiﬁcation during an asthma exacerbation
[42].In the present study, the eosinophilic count was signiﬁ-
cantly correlated directly with the EBC-NOx and inversely
with EBC-pH. Such correlations of eosinophils and exhaled
NOx [43] and pH [39] have been previously reported. The
eNO increased production is due to the activation of iNOS,
which is thought to be upregulated by inﬂammatory cytokines
particularly via eosinophilic activation and airway epithelium
[44]. The vesicles of eosinophils contain vacuolar hydrogen-
adenosine triphosphatase, which could be responsible for an
increased hydrogen ions release [45]. Also eosinophilic gran-
ules contain eosinophil peroxidase which catalyzes a reaction
between hydrogen peroxide and chloride ions to form hypo-
chlorous acid. This acid is highly volatile and might be respon-
sible for the acidiﬁcation of expired breath condensate of
patients with asthma [39]. Although asthma is not a neutro-
philic inﬂammation, we found a signiﬁcant inverse correlation
between EBC-pH and neutrophilic count. The presence of neu-
trophils can lead to acidiﬁcation of EBC by releasing myelo-
peroxidase which acts in the same way as eosinophils
peroxidase [46].
In our work, the spirometric parameters of airway obstruc-
tion were signiﬁcantly correlated inversely with EBC-NOx and
directly with EBC-pH. The spirometric data inverse correla-
tion with eNO was demonstrated before by some authors
[43]. It was demonstrated that eNO levels rise in asthmatic pa-
tients before drop in PEFR; showing great promise in identify-
ing impending asthma exacerbations [28]. It was also suggested
that eNO levels do not correlate with disease severity but com-
plement symptoms and spirometric assessments in persistent
asthmatic patients [23]. A lower EBC-pH was noticed is asso-
ciated with a decreased FEV1 in asthmatic children, and with
recent increased bronchodilator usage, but not with night-time
wheeze. It may be that pH reﬂects the asthma severity at the
time of sampling, but may not necessarily be an indicator of
asthma exacerbation [47].
Exhaled breath condensate collection and processing is a
non-invasive, safe and relatively simple to perform. EBC-
NOx was signiﬁcantly higher and EBC-pH was signiﬁcantly
lower in asthmatic patients than in control subjects. Moreover,
asthmatics receiving ICS had a signiﬁcantly lower EBC-NOx
level than those not. Levels of EBC-NOx and EBC-pH were
signiﬁcantly correlated and both of them showed signiﬁcant
correlations with spirometric parameters of airway obstruc-
tion. EBC biomarkers may prove a valuable diagnostic tool
by providing an objective means to deﬁne the severity of asth-
ma and to tailor anti-inﬂammatory medications. The useful-
ness of such biomarkers would be of great value, should
their changes precede those of physiological parameters. More
focus should be emphasized on standardization of collection
procedures, validation of sensitive analyses and establishing
reference values.References
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